Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag

Cytotherapy

Volumn 9, Issue 1, 2007, Pages 23-34

  Felicetti, P ^a   Mennecozzi, M ^a   Barucca, A ^b   Montgomery, S ^a   Orlandi, F ^a   Manova, K ^a   Houghton, A N ^a   Gregor, P D ^a   Concetti, A ^b   Venanzi, F M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Breast cancer; DNA vaccine; Melanoma; Neovasculature; Tumor immunology.

Indexed keywords

ANTHRAX TOXIN RECEPTOR 1, HUMAN; CANCER VACCINE; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; MEMBRANE PROTEIN; OXIDOREDUCTASE; RECOMBINANT PROTEIN; TUMOR PROTEIN; TYRP1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; EXPERIMENTAL MELANOMA; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IN SITU HYBRIDIZATION; MOUSE; PATHOLOGY; RAT; SURVIVAL; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIGENS, DIFFERENTIATION; BLOTTING, WESTERN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IN SITU HYBRIDIZATION; MAMMARY NEOPLASMS, ANIMAL; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; OXIDOREDUCTASES; RATS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 34247116060     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240601048369     Document Type: Article

References (59)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64 (Pubitemid 26272076)
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
3. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72 (Pubitemid 37328923)
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
5. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-16
6. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47 (Pubitemid 36818244)
7. Huang X, Wong MK, Yi H et al . Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer Res 2002;62:5727-35 (Pubitemid 35204728)
8. Drevs J, Muller-Driver R, Wittig C et al . PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-22 (Pubitemid 34791068)
9. Huang J, Frischer JS, Serur A et al . Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-90 (Pubitemid 36760047)
10. Jeffes EW, Zhang JG, Hoa N et al . Antiangiogenic drugs synergize with a membrane macrophage colony-stimulating factor-based tumor vaccine to therapeutically treat rats with an established malignant intracranial glioma. J Immunol 2005;174:2533-43 (Pubitemid 40279666)
11. Xiang R, Mizutani N, Luo Y et al . A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005;65:553-61
12. Morgan B, Thomas AL, Drevs J et al . Dynamic contrastenhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64 (Pubitemid 46606209)
13. Hurwitz H, Fehrenbacher L, NovotnyWet al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42 (Pubitemid 38702844)
14. Motzer RJ, Rini BI, Michaelson MD. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase II trial. J Clin Oncol , 2004. ASCO Annual Meeting. Proceedings (Post-Meeting Edition). 2004;22:145 (July 15 Suppl.)
15. Willett CG, Boucher Y, di Tomaso E et al . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7 (Pubitemid 38524883)
16. Wei YQ , Wang QR, Zhao X et al . Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000;6:1160-6
17. Wei YQ , Huang MJ, Yang L et al . Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001;98:11545-50 (Pubitemid 32928765)
18. Li Y, Wang MN, Li H et al . Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002;195:1575-84 (Pubitemid 34666071)
19. Niethammer AG, Xiang R, Becker JC et al . A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-75 (Pubitemid 36019421)
20. He QM, Wei YQ , Tian L et al . Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003;278:21831-6 (Pubitemid 36792588)
21. Venanzi FM, Stable A, Papa S et al. Effect of immunoprevention of neu transgenic breast cancer by targeting both cancer and endothelial cells. In: AACR Annual Meeting, 2002 April 6-10, San Francisco, CA. Proceeding of the American Association for Cancer Research 2002;43:90, abstract 448
22. St Croix B, Rago C, Velculescu V et al . Genes expressed in human tumor endothelium. Science 2000;289:1197-202 (Pubitemid 30650733)
23. Rmali KA, Puntis MC, Jiang WG. Prognostic values of tumor endothelial markers in patients with colorectal cancer. World J Gastroenterol 2005;11:1283-6 (Pubitemid 40425909)
24. Carson-Walter EBWD, Nanda A, Vogelstein B et al . Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61:6649-55 (Pubitemid 32896479)
25. Nanda A, Carson-Walter E, Seaman S et al . TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 2004;64:817-20 (Pubitemid 38176877)
26. Hotchkiss KA, Basile CM, Spring SC et al . TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 2005;305:133-44 (Pubitemid 40380660)
27. Bradley KA, Mogridge J, Mourez M et al . Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9 (Pubitemid 33051239)
28. Scobie HM, Young JA. Interactions between anthrax toxin receptors and protective antigen. Curr Opin Microbiol 2005;8:106-12 (Pubitemid 40203233)
29. Bonuccelli G, Sotgia F, Frank PG et al . ATR/TEM8 is highly expressed in epithelial cells lining Bacillus anthracis' three sites of entry: implications for the pathogenesis of anthrax infection. Am J Physiol Cell Physiol 2005;288:C1402-10 (Pubitemid 40991077)
30. Armstrong AJ, Carducci MA. Advanced prostate cancer: the future. Can J Urol 2005;12 Suppl 2:42-7
31. Todorova K, Ignatova I, Tchakarov S et al . Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun 2005;5:1-8
32. Kinoshita Y, Kuratsukuri K, Landas S et al . Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30:628-36
33. Mincheff M, Zoubak S, Makogonenko Y. Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther 2006;13:436-44
34. Chianese-Bullock KA, Woodson EM, Tao H et al . Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412-9 (Pubitemid 40962336)
35. Dudley ME, Wunderlich JR, Robbins PF et al . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4 (Pubitemid 35231542)
36. Amici A, Venanzi FM, Concetti A. Genetic immunization against neu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998;47:183-90 (Pubitemid 29009672)
37. Naftzger C, Takechi Y, Kohda H et al . Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 1996;93:14809-14 (Pubitemid 26419051)
38. Weber LW, Bowne WB, Wolchok JD et al . Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998;102:1258-64 (Pubitemid 28436286)
39. Bowne WB, Srinivasan R, Wolchok JD et al . Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-22 (Pubitemid 30002353)
40. Gold JS, Ferrone CR, Hawkins WG et al . A single heteroclitic epitope determines cancer immunity following xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003;170:5188-94 (Pubitemid 36554751)
41. Muller WJ, Sinn E, Pattengale PK et al . Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15
42. Nanni P, Pupa SM, Nicoletti G et al . p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87:186-94 (Pubitemid 30434343)
43. Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-14
44. Ross HM, Weber LW, Wang S et al . Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 1997;3:2191-6 (Pubitemid 28133135)
45. Dyall R, Bowne WB, Weber LWet al . Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-61 (Pubitemid 28516100)
46. Hawkins WG, Gold JS, Dyall R et al . Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000;128:273-80 (Pubitemid 30622495)
47. Herr W, Schneider J, Lohse AWet al . Detection and quantification of blood-derived CD8-T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-42 (Pubitemid 26173515)
48. Esserman LJ, Lopez T, Montes R et al . Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999;47:337-42 (Pubitemid 29151833)
49. Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 2001;167:3367-74 (Pubitemid 32852580)
50. Foy TM, Bannink J, Sutherland RA et al . Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 2001;19:2598-606 (Pubitemid 32234278)
51. Quaglino E, Iezzi M, Mastini C et al . Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004;64:2858-64 (Pubitemid 38500626)
52. Chen Y, Hu D, Eling DJ et al . DNA vaccines encoding fulllength or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998;58:1965-71 (Pubitemid 28217474)
53. Pilon SA, Piechocki MP, Wei WZ. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 2001;167:3201-6 (Pubitemid 32852559)
54. Disis ML, Shiota FM, McNeel DG, Knutson KL. Soluble cytokines can act as effective adjuvants in plasmid DNAvaccines targeting self tumor antigens. Immunobiology 2003;207:179-86 (Pubitemid 36626300)
55. Croci S, Nicoletti G, Landuzzi L et al . Immunological prevention of a multigene cancer syndrome. Cancer Res 2004;64:8428-34 (Pubitemid 39491783)
56. Lin CC, Chou CW, Shiau AL et al . Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 2004;10:290-301
57. Spadaro M, Ambrosino E, Iezzi M et al . Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant Interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin Cancer Res 2005;11:1941-52 (Pubitemid 40471860)
58. Perales MA, Blachere NE, Engelhorn ME et al . Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 2002;12:63-71 (Pubitemid 34087900)
59. Nair S, Boczkowski D, Moeller B et al . Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003;102:964-71 (Pubitemid 36917791)